{"id":65053,"date":"2025-12-20T10:14:52","date_gmt":"2025-12-20T10:14:52","guid":{"rendered":"https:\/\/crowdfundjunction.com\/blog\/trump-secures-deals-with-nine-pharma-firms-to-lower-us-drug-prices-avert-tariffs\/"},"modified":"2025-12-20T10:14:52","modified_gmt":"2025-12-20T10:14:52","slug":"trump-secures-deals-with-nine-pharma-firms-to-lower-us-drug-prices-avert-tariffs","status":"publish","type":"post","link":"https:\/\/crowdfundjunction.com\/blog\/trump-secures-deals-with-nine-pharma-firms-to-lower-us-drug-prices-avert-tariffs\/","title":{"rendered":"Trump secures deals with nine pharma firms to lower US drug prices, avert tariffs"},"content":{"rendered":"

(Originally posted on : Invezz )<\/b>
\n<\/p>\n

\n

US President Donald Trump announced deals with nine major pharmaceutical companies on Friday to lower US drug prices in exchange for three-year exemptions from threatened tariffs on pharmaceutical imports.<\/a><\/p>\n

The agreements bring the total number of drugmakers aligned with Trump\u2019s pricing initiative to 14 of the 17 companies the administration targeted this year.<\/p>\n

The latest round represents the largest pharmaceutical pricing agreement announced to date, covering price reductions on treatments for diabetes, rheumatoid arthritis, multiple sclerosis, asthma, COPD, hepatitis B and C, HIV, and certain cancers.\u200b<\/p>\n

Nine firms join Trump\u2019s drug-price plan<\/h2>\n


\n Copy link to section<\/span>
\n <\/a><\/p>\n

The nine companies announcing deals on Friday are Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech (Roche), Gilead Sciences, GSK, Merck, Novartis, and Sanofi.<\/p>\n

Each firm is committed to implementing \u201cMost Favored Nation\u201d pricing for Medicaid, the federal health insurance program for low-income Americans, ensuring that drugs priced higher in the US than in comparable nations will be discounted to international levels.<\/p>\n

The companies will also launch new medications at most-favored-nation prices and offer primary care and specialty medications through the TrumpRx platform, a direct-to-consumer website set to launch in January 2026.\u200b<\/p>\n

Several signatory firms have additionally pledged to donate active pharmaceutical ingredients to America\u2019s Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to support emergency preparedness for pandemics and national security crises.<\/p>\n

In return for these commitments, the Trump administration granted each company a three-year tariff exemption that shields them from threatened 100% tariffs on brand pharmaceutical imports and 15% tariffs on European Union medicines.\u200b<\/p>\n

According to senior administration officials, approximately 30 to 40% of Medicaid drugs will be impacted by the price reductions.<\/p>\n

The TrumpRx platform will guide consumers to manufacturers\u2019 direct-to-consumer sales channels where they can purchase medications at negotiated discounts, a model that contrasts with traditional insurance-based purchasing and appeals to uninsured or self-insured Americans seeking cash discounts.<\/p>\n

Tariff relief tied to discounts<\/h2>\n


\n Copy link to section<\/span>
\n <\/a><\/p>\n

The tariff component represents Trump\u2019s primary leverage in these negotiations.<\/p>\n

Earlier announcements with Pfizer and AstraZeneca followed similar frameworks: price reductions tied to three-year tariff holidays and commitments to increase domestic manufacturing.<\/p>\n

The administration signaled willingness to use tariff threats aggressively, with Trump administration officials explicitly acknowledging that tariff pressure drove companies to the negotiating table.\u200b<\/p>\n

Three major pharmaceutical firms remain unsigned as of December 19, creating potential leverage for further negotiations heading into 2026.<\/p>\n

Democratic lawmakers immediately demanded transparency regarding cost savings and questioned whether the confidential deals truly benefit patients or merely shift financial burdens without delivering meaningful price relief.<\/p>\n

Health policy experts noted that while Medicaid beneficiaries typically pay little to nothing for medications under existing programs, cash-paying and uninsured patients could see substantial savings through TrumpRx direct purchases, potentially providing greater relief than Medicaid rate changes.\u200b<\/p>\n

Pharmaceutical industry groups acknowledged that the deals represent material concessions but argued that US pricing strategies have historically supported robust research and development investments.<\/p>\n

Analysts warned that aggressive domestic price controls could discourage new drug development and slow innovation, a concern Trump administration officials dismissed, noting that companies\u2019 willingness to sign indicates sustainable profitability at lower price points.\u200b<\/p>\n

\u200b<\/h2>\n


\n Copy link to section<\/span>
\n <\/a> <\/div>\n

Source link <\/a>
\n
<\/p>\n","protected":false},"excerpt":{"rendered":"

(Originally posted on : Invezz ) US President Donald Trump announced deals with nine major pharmaceutical companies on Friday to lower US drug prices in exchange for three-year exemptions from threatened tariffs on pharmaceutical imports. The agreements bring the total number of drugmakers aligned with Trump\u2019s pricing initiative to 14 of the 17 companies the […]<\/p>\n","protected":false},"author":3947362395,"featured_media":65054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"categories":[38],"tags":[],"_links":{"self":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts\/65053"}],"collection":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/users\/3947362395"}],"replies":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/comments?post=65053"}],"version-history":[{"count":0,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/posts\/65053\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/media\/65054"}],"wp:attachment":[{"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/media?parent=65053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/categories?post=65053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/crowdfundjunction.com\/blog\/wp-json\/wp\/v2\/tags?post=65053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}